Page 4 - ஆதரவு மூலதனம் நிறுவனம் ஆராய்ச்சி துறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Aegis Capital Corp Acted as Sole Bookrunner on a $8 5 Million Follow-On Offering for Medigus Ltd (Nasdaq: MDGS)
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Aegis Capital Corp Acted as Sole Bookrunner on a $8 5 Million Follow-On Offering for Medigus Ltd (Nasdaq: MDGS)
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Aegis Capital Corp Acted as Sole Bookrunner on a $39 7 Million Upsized Follow-On Offering for Document Security Systems, Inc (NYSE American: DSS)
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Aegis Capital Corp. Acted as Sole Bookrunner on a $12.1 Million Follow-On Offering for BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV)
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses. The Company had been developing M-001, a novel influenza vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of influenza virus strains. In October 2020, the Company completed a Phase 3 clinical trial of M-001 which failed to meet the trial s primary and secondary efficacy endpoints. The Company is now pursui
Aegis Capital Corp. acted as Sole Bookrunner on a $14.4 Million Bought Deal Offering for Avinger, Inc. (NASDAQ: AVGR)
About Avinger, Inc
.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.